Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

By H. Tilly, M. G. Silva, U. Vitolo, A. Jack, M. Meignan, A. López-Guillermo, J. Walewski, M. André, Peter W M Johnson, M. Pfreundschuh and 1 more. Annals of Oncology, 2012

856 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/533499759847a6fe354e71aaeaa54ddcc1c518e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Neelapu
2. Lei Feng
3. M. Crump
4. E. Van Den Neste
5. U. Farooq
6. J. Kuruvilla
7. M. Maurer
8. J. Wiezorek

Citations in the corpus

• Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. (2017, background): “Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), with 27,650 estimated new cases diagnosed in the United States in 2016 and an annual incidence of 3 to 4 per 100,000 persons in Europe.(1,2) Survival rates have improved over the last several decades, wit”